GHRS logo

GH Research (GHRS) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Ireland

IPO:

25 June 2021

Indexes:

Not included

Description:

GH Research focuses on developing innovative therapies for patients with treatment-resistant psychiatric disorders. The company specializes in psychedelic research, aiming to create safe and effective treatments that improve mental health outcomes. Their goal is to transform the way these conditions are treated and enhance patients' quality of life.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

20 Nov '24 HC Wainwright & Co.
Buy
18 Nov '24 Canaccord Genuity
Buy
05 Sept '24 HC Wainwright & Co.
Buy
04 Sept '24 JMP Securities
Market Outperform
31 July '24 HC Wainwright & Co.
Buy
07 May '24 HC Wainwright & Co.
Buy
06 May '24 Canaccord Genuity
Buy
04 Mar '24 HC Wainwright & Co.
Buy
01 Mar '24 JMP Securities
Market Outperform
18 Jan '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
GHRS
globenewswire.com14 November 2024

DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided updates on its business.

GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
GHRS
zacks.com09 September 2024

GH Research (GHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
GHRS
zacks.com09 September 2024

GH Research (GHRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
GHRS
globenewswire.com03 September 2024

DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business.

Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
GHRS
Zacks Investment Research13 May 2024

GH Research (GHRS) is a strong stock that has caught the attention of investors seeking to capitalize on stocks showing recent price strength.

How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
GHRS
Zacks Investment Research05 March 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FAQ

  • What is the primary business of GH Research?
  • What is the ticker symbol for GH Research?
  • Does GH Research pay dividends?
  • What sector is GH Research in?
  • What industry is GH Research in?
  • What country is GH Research based in?
  • When did GH Research go public?
  • Is GH Research in the S&P 500?
  • Is GH Research in the NASDAQ 100?
  • Is GH Research in the Dow Jones?
  • When was GH Research's last earnings report?
  • When does GH Research report earnings?
  • Should I buy GH Research stock now?

What is the primary business of GH Research?

GH Research focuses on developing innovative therapies for patients with treatment-resistant psychiatric disorders. The company specializes in psychedelic research, aiming to create safe and effective treatments that improve mental health outcomes. Their goal is to transform the way these conditions are treated and enhance patients' quality of life.

What is the ticker symbol for GH Research?

The ticker symbol for GH Research is NASDAQ:GHRS

Does GH Research pay dividends?

No, GH Research does not pay dividends

What sector is GH Research in?

GH Research is in the Healthcare sector

What industry is GH Research in?

GH Research is in the Biotechnology industry

What country is GH Research based in?

GH Research is headquartered in Ireland

When did GH Research go public?

GH Research's initial public offering (IPO) was on 25 June 2021

Is GH Research in the S&P 500?

No, GH Research is not included in the S&P 500 index

Is GH Research in the NASDAQ 100?

No, GH Research is not included in the NASDAQ 100 index

Is GH Research in the Dow Jones?

No, GH Research is not included in the Dow Jones index

When was GH Research's last earnings report?

GH Research's most recent earnings report was on 14 November 2024

When does GH Research report earnings?

The next expected earnings date for GH Research is 28 February 2025

Should I buy GH Research stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions